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Abstract
Background: Lassa fever (LF), an often-fatal hemorrhagic disease caused by Lassa virus (LASV), is a major public health
threat in West Africa. When the violent civil conflict in Sierra Leone (1991 to 2002) ended, an international consortium
assisted in restoration of the LF program at Kenema Government Hospital (KGH) in an area with the world’s highest
incidence of the disease.
Methodology/Principal Findings: Clinical and laboratory records of patients presenting to the KGH Lassa Ward in the post-
conflict period were organized electronically. Recombinant antigen-based LF immunoassays were used to assess LASV
antigenemia and LASV-specific antibodies in patients who met criteria for suspected LF. KGH has been reestablished as a
center for LF treatment and research, with over 500 suspected cases now presenting yearly. Higher case fatality rates (CFRs)
in LF patients were observed compared to studies conducted prior to the civil conflict. Different criteria for defining LF
stages and differences in sensitivity of assays likely account for these differences. The highest incidence of LF in Sierra Leone
was observed during the dry season. LF cases were observed in ten of Sierra Leone’s thirteen districts, with numerous cases
from outside the traditional endemic zone. Deaths in patients presenting with LASV antigenemia were skewed towards
individuals less than 29 years of age. Women self-reporting as pregnant were significantly overrepresented among LASV
antigenemic patients. The CFR of ribavirin-treated patients presenting early in acute infection was lower than in untreated
subjects.
Conclusions/Significance: Lassa fever remains a major public health threat in Sierra Leone. Outreach activities should
expand because LF may be more widespread in Sierra Leone than previously recognized. Enhanced case finding to ensure
rapid diagnosis and treatment is imperative to reduce mortality. Even with ribavirin treatment, there was a high rate of
fatalities underscoring the need to develop more effective and/or supplemental treatments for LF.
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Introduction
Viral hemorrhagic fevers are among the most feared diseases
due to their high case fatality rates (CFRs), severe clinical
presentations and ease of transmission. Unlike most viral
hemorrhagic fevers, which are recognized only when outbreaks
occur, Lassa fever (LF) is endemic in West Africa, with an
estimated tens of thousands of cases annually [1]. LF was first
recognized in 1969 following the deaths of two missionary nurses
during an outbreak in northeastern Nigeria [2–4]. The popula-
tions of Sierra Leone, Guinea, Liberia and other West African
countries were subsequently also shown to be at risk for LF [5–8].
Humans become infected with LASV by exposure to the excreta
of its reservoir Mastomys natalensis, also known as the ‘‘multi-
mammate rat’’ [9,10]. As in the first reported cases, secondary
human-to-human transmission of LASV also occurs through
direct contact with infected blood or bodily secretions. Deaths
among nurses, doctors and other healthcare workers occasionally
occur when adherence to barrier nursing and contact precautions
are not maintained [11].
After an incubation period of 5–16 days, LF typically begins
with fever and a host of other non-specific manifestations,
including headache, sore throat, myalgia, and gastrointestinal
symptoms [5,12–16]. More specific manifestations such as
conjunctival injection, retrosternal pain, facial swelling, and
mucosal and gastrointestinal bleeding occur in less than a third
of cases. The non-specific clinical presentation makes LF
extremely difficult to recognize on clinical grounds alone,
especially in the early phases. Prompt laboratory diagnosis is
therefore essential. Unfortunately, laboratory diagnosis has gen-
erally not been available in the endemic areas, impeded by the
unavailability of diagnostic reagents, which have traditionally been
based on inactivated cultures of LASV, a process that can only
safely be performed in the very few high containment laboratories
around the world. Death from LF is attributed to diminished
effective circulating volume, shock, and multi-organ system failure
[17]. The antiviral drug ribavirin can be effective, but only when
given early in the course of disease, ideally within the first six days
[18]. There is no approved LF vaccine.
The Eastern Province of Sierra Leone is considered to have the
world’s highest LF incidence [6]. In 1976, the Sierra Leone
Ministry of Health and Sanitation (MoHS) with support from the
United States Centers for Disease Control and Prevention (CDC)
established LF treatment wards and a diagnostic laboratory in the
Eastern Province [19]. Kenema Government Hospital (KGH) was
an important site for LF clinical and laboratory research
throughout the remainder of the 1970s and the 1980s
[12,13,20]. The violent civil conflict from 1991 to 2002, sometimes
referred to as the Blood Diamonds War, forced suspension of
CDC involvement in LF research at KGH in 1993. Following the
cessation of hostilities, a consortium of LF researchers in close
collaboration with the MoHS began rebuilding the scientific
infrastructure at KGH, with the development of improved
laboratory diagnosis for LF as a major focus [19,21–24]. Here,
we summarize the demographics and epidemiology of patients
presenting to KGH with suspected LF in the decade following the
end of the civil conflict.
Methods
Ethics statement
The Tulane University Institutional Review Board and the
Sierra Leone Ethics Committee approved this project. Patients
were referred to the KGH Lassa Ward from regional health
centers or the hospital’s general ward on the basis of suspicion of
LF. Patients were cared for by the ward’s trained staff [19]. All
adult subjects provided written informed consent to analyze and
publish laboratory and clinical data. A parent or guardian of any
child participant provided written informed consent on their
behalf.
Patient selection and data collection
To be considered for admission to the KGH Lassa Ward,
subjects were required to satisfy the LF case definition criteria
(Table 1) according to an evaluation questionnaire. In many cases,
we only received blood samples from referral centers, and survival
outcome results were not always known. The sample population
for this work was based on the availability of Ag and IgM ELISA
test results, regardless of whether these patients presented to KGH.
Since screening based on anti-LASV IgG-capture ELISA was not
routinely conducted at the KGH until 2011, it was not considered
an inclusion criterion. Observations were excluded if they were for
subjects residing outside of Sierra Leone (the KGH Lassa
Laboratory routinely receives samples from Liberia for testing,
and occasionally receives samples from Guinea) or if they were
classified as contacts of an index LF case. We imposed several
additional criteria in an effort to exclude invalid test results.
Specifically, we required that raw laboratory data be available for
both the Ag and IgM ELISA tests. Also, raw laboratory data was
considered valid only if each of its OD values was non-negative
(for the patient sample and its positive and negative controls) and
the OD values for the positive controls were greater than those for
its corresponding negative control. These restrictions resulted in
the n = 1740 observations used for the study (Table S1). These
samples were used to generate the final test results using a cutoff-
based approach. The test result cutoffs were calculated by year of
presentation to control for the environmental changes and
temporal improvements at the KGH laboratory. These results
were then linked to all of the clinical, epidemiological, and
treatment data available. The study was not designed as a
longitudinal study, but we did observe n = 362 serial samples to
address questions involving LF seroconversions or changes in Ag
or antibody levels.
All demographic, clinical, and treatment data were entered into
a Microsoft Access database using electronic questionnaire forms.
Raw laboratory data was maintained using Excel spreadsheets
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with standard structures. The data were progressively cleaned and
curated via regular on-and off-site data audits, where data were
checked against their questionnaire forms and laboratory note-
books. Raw laboratory data were compiled using a suite of
Microsoft Excel macros. All available data sources were linked
using the SAS System (version 9.3; SAS Institute, Cary, NC.
LF recombinant antigen immunoassays at KGH
We have focused on the development of recombinant antigen-
based immunoassays for diagnosis of LF at KGH. These assays
have the safety advantages of not requiring BSL-4 cell culture for
production [22,24]. Performance of the Recombinant Lassa
(ReLASV) Diagnostics system versus detection of LASV viremia
by reverse transcriptase polymerase chain (RT-PCR) was evalu-
ated in a clinical study conducted at KGH in 2012–13
(unpublished data). Criteria for inclusion in the clinical study
were based on the suspected LF case definition (Table 1). Limits of
detection and quantitation of the recombinant antigen-based LF
enzyme-linked immunosorbent assays (ELISA) used were based on
the upper 95th percentile obtained with a panel of sera from U.S.
and Sierra Leonean donors lacking detectable LASV antigens or
immunoglobulin M or G (IgM, and IgG) antibodies to LASV
recombinant proteins. IgG depletion studies (protein A) demon-
strated that the LASV IgM assay is only detecting anti-LASV IgM,
not IgG and conversely that the IgG assay has a high specificity for
anti-LASV IgG. Upon presentation to the LF clinical study
program, screening with the ReLASV diagnostic assays, upon
presentation to the LF clinical study program, was capable of
identifying 95% of active LF cases as confirmed by RT-PCR
performed at KGH, rising IgM titers or IgM to IgG seroconver-
sion (Table S2) (unpublished data). The diagnostic assays being
utilized miss a low percentage (,5%) of resolving or less severe
cases with low virus load that are generally associated with low
mortality. Combining the NP antigen detection (Ag-capture
ELISA) results with anti-LASV IgM reactivity (IgM-capture
ELISA) generated a 98% negative predictive value, which further
demonstrates its capability as an on-site point of care screening
protocol. A lateral flow immunoassay (rapid diagnostic test, RDT)
requiring only a drop of blood (30 ml) obtained with a safety lancet
and capable of detecting LASV antigenemia within 15 minutes
was also developed.
Sequence variability of LASV challenges both immune-based
and molecular assays [25]. The immunoassays used in the
current study are designed to detect antigens of LASV
circulating in Sierra Leone or surrounding countries or
antibodies to these viruses. We used high-throughput sequenc-
ing to generate a catalogue of LASV genomic data (unpublished
data). We confirmed prior studies indicating that there are three
diverse LASV lineages in Nigeria (I–III), but only a single
lineage (IV) in Sierra Leone. We have detected only lineage IV
LASV in Sierra Leone in these genomic screens. The Ag-
capture ELISA we have developed using LASV Josiah (lineage
IV) recombinant proteins and antibodies to these proteins show
reactivity to BSL-4 grown LASV Josiah, but reduced sensitivity
to LASV of Nigerian lineages II and III. The ReLASV
immunoassays failed to react with New World arenavirus
antigens (Junin or Pichinde viruses) or several RNA or DNA
virus antigens (dengue virus type 1, 2, 3, 4, influenza A virus,
vesicular stomatitis virus, respiratory syncytial virus, cytomeg-
alovirus, poxvirus and others).
Statistical analysis
Data were analyzed using the SAS System (version 9.3; SAS
Institute, Inc., Cary, NC). Hypotheses involving dichotomous
response variables were tested using Fisher’s exact test or logistic
regression. For logistic regression models with multiple indepen-
dent predictors, all pairwise interaction terms were included in
the model. Count outcomes were modeled using Poisson
regression, and distributional comparisons were carried out
using the Kolmogorov-Smirnov approach. Gaussian kernel
smoothing was used to smooth the categorical serostatus age
distributions. Analyses were two-tailed with a significance
threshold set at p,.05
Accession number
Recombinant nucleoprotein, glycoprotein and Z protein from
lineage IV Lassa virus Josiah strain (ADY11071) were use used in
the IgM and IgG-capture ELISAs. These recombinant proteins
were also used to immunize goats and mice for use in the ReLASV
Ag-capture ELISA and RDT.
Results
Reestablishment of KGH as a treatment and research
center for LF
Admission to the KGH Lassa Ward on the basis of clinical
suspicion of LF continued throughout the extremely difficult years
of the civil conflict, with up to 500 suspected cases in some years
[1,19,26]. Paradoxically, after cessation of hostilities, and with the
MoHS facing an enormous rebuilding challenge and the departure
of many of the humanitarian assistance groups previously
confronting LF, there was a period where few resources were
available for patients suffering from LF; from 2004 to 2008 there
were 405 confirmed or probable LF cases presenting to KGH,
with a peak of 227 in 2004. Most were diagnosed only on clinical
grounds or occasionally using nonrecombinant antigen-capture
ELISA [27].
Our group and others participated in efforts to restore and
enhance both clinical and laboratory-based research on LF at
KGH [19]. Recombinant antigen-based ELISAs were developed
and implemented and have been used consistently at the KGH
Lassa Ward since 2008, with the addition of the lateral flow
immunoassay in 2010. The number of suspected LF cases
presenting to KGH dramatically increased from 85 in 2008 to
529 in 2012, with a peak of 575 in 2011 (Fig. 1). The number of
patients admitted to the KGH Lassa Ward peaked at 164 in 2010,
then decreased to 109 in 2012 (Fig. 1). The reduction in admitted
patients after 2010 corresponds to the introduction of the LF
Author Summary
Lassa fever (LF) is a major public health threat in West
Africa. After the violent civil conflict in Sierra Leone (1991
to 2002) ended, the LF research program at Kenema
Government Hospital (KGH) was reestablished. Higher
CFRs in LF patients were observed compared to studies
conducted prior to the civil conflict. The criteria used for
defining the stages of LF and differences in sensitivity of
the assays used likely account for these differences. LF may
be more widespread in Sierra Leone than recognized
previously. Peak presentation of LF cases occurs in the dry
season, which is consistent with previous studies. Our
studies also confirmed reports conducted prior to the civil
conflict that indicate that infants, children, young adults,
and pregnant women are disproportionately impacted by
LF. High fatality rates were observed among both ribavirin
treated and untreated patients, which underscores then
need for better LF treatments.
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lateral flow immunoassay, which permits avoidance of some
unnecessary admissions to the Lassa ward.
A positive result on the LASV antigen-capture ELISA or lateral
flow immunoassay indicates that the subject is viremic and
confirms the clinical diagnosis of LF. Among patients meeting the
case definition of LF (Table 1) who were evaluated at the KGH
Lassa Ward from 2008–2012, 11% (190/1740) were antigenemic
on the first blood draw. These patients were also evaluated for the
presence of anti-LASV IgM: 8% (140/1740) were Ag+/IgM2,
while 3% (50/1740) were Ag+/IgM+. Among non-antigenemic
patients, 23% (407/1740) have serum IgM antibodies to LASV. As
discussed below, the presence of anti-LASV IgM antibodies can
represent several stages in LF or a prior symptomatic or
asymptomatic LASV infection. Diagnosis of recent LF in admitted
subjects without antigenemia is revealed in some cases by
additional blood draws to determine if the subject demonstrates
an increasing anti-LASV IgM titer or shows a class switch to anti-
LASV IgG. Of the suspected LF patients 65% (1143/1740) were
Ag2/IgM2 and therefore considered to have a non-Lassa febrile
illness (NLFI).
Case fatality rates by serostatus
The overall CFR in antigenemic LF cases (Ag+/IgM6) with
verifiable outcomes was 69% (109/158). The CFR was similar in
Ag+ cases regardless of their anti-LASV IgM result (62% (28/45)
for Ag+/IgM2 and 72% (81/113) for Ag+/IgM+ cases; Fig. 2A).
In contrast, the CFR in Ag2/IgM+ patients (first blood draw) was
29% (46/161), which was not statistically different from the NLFI
patients (36% [65/182]; Fig. 2A, Table S1). All subjects included
in the study met the case definition for LF. The patients were
generally severely ill, irrespective of whether they were diagnosed
with LF, which likely accounts for the high CFR in the Ag2/
IgM+ and Ag2/IgM2 groups. Nearly all patients were
unresponsive to anti-malaria and antibiotic therapy, and remained
ill. Despite anti-malaria treatment, we found that more than half
of a sample of NLFI subjects analyzed had detectable levels of
Plasmodium falciparum (data not shown). HIV testing was not
performed. Studies of NLFIs in this population are of interest, but
an extensive characterization was not possible due to resource and
infrastructure constraints during this project period. It should be
noted that CFRs are based on patients with verifiable outcomes
from medical records. The CFRs in the Ag2 serogroup patients,
who were admitted to the Lassa Ward, are almost certainly
inflated relative to patients in these serogroups who were not
admitted.
While Ag-positive subjects at the regional health posts were
usually transferred to KGH, some did not physically present to
KGH and their survival outcomes could not be determined. A few
Ag+ cases refused admission or informed consent, and 32 Ag+
subjects without outcome data represented referred samples or
those that refused admission or informed consent (Table S1).
Table 1. Case definition for suspected cases of LF.
N Known exposure to a person suspected to have Lassa fever
N Fever .38uC for less than three weeks PLUS
N Absence of signs of local inflammation AND
N Two major signs or one major and two minor signs
Major Signs Minor Signs
N Bleeding N Headache
N Swollen neck or face N Sore throat
N Conjunctivitis or sub-conjunctival hemorrhage N Vomiting
N Spontaneous abortion N Diffuse abdominal pain/tenderness
N Petechial or hemorrhagic rash N Chest/retrosternal pain
N New onset of tinnitus or altered hearing N Cough
N Persistent hypotension N Diarrhea
N Absence of clinical response after 48 hrs to anti-malarial and/or broad spectrum antibiotic
therapy
N Generalized myalgia or arthralgia
N Profuse weakness
Modified from Khan et al., 2008 [19].
doi:10.1371/journal.pntd.0002748.t001
Figure 1. Suspected cases of LF evaluated at the KGH Lassa
Laboratory and numbers of patients admitted to the KGH
Lassa Ward, 2008–12. Non-admitted patients include those where
only blood samples were submitted for screening from referral health-
posts, patients dying en route to the hospital (DOA=dead on arrival),
and patients not meeting the LF suspected case criteria (Table 1).
Characteristics of study patients are compiled in Table S1.
doi:10.1371/journal.pntd.0002748.g001
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Including these 32 Ag+ subjects (and assuming they survived
LASV infection) with the 158 Ag+ patients with verifiable
outcomes results in a CFR of 57% (109/190). This lower CFR
requires the caveat that verifiable outcome data was not obtained
for non-admitted subjects, and it is unlikely that all survived.
In most viral infections antiviral IgM arises early after
infection, and then is replaced by antiviral IgG. Prior studies
have included IgM+ subjects as acute LF cases [27,28].
Including Ag2/IgM+ with Ag+/IgM6 patients results in a
CFR of 49% (155/319, Fig. 2B, Tables S1, S3). Ag2 patients
that demonstrated increasing levels of IgM suggest the
possibility of a resolving infection (post-acute LF) or a stage of
early convalescence. Over 84% (70/83) of Ag2/IgM+ patients
for whom more than one IgM test result was available did not
show a significant increase in anti-LASV IgM levels during their
stay in the Lassa Ward, suggesting that the illness for which they
presented was not LF. Only one (1/13, 8%) fatality was noted
among Ag2/IgM+ patients with rising anti-LASV IgM levels.
These patients with rising IgM levels (post-acute or early
convalescence) generally had only moderately elevated aspartate
aminotransferase levels (data not shown), which is an indicator
of severity in LF.
IgG-capture ELISA was implemented for routine diagnostic
testing of suspected LF patients in 2011. The prevalence of anti-
LASV IgG was significantly higher in Ag2/IgM+ patients, than
in Ag2/IgM2 patients and patients in other serogroups
(Fig. 3A). Among subjects presenting with a NLFI, as
determined by the absence of LASV Ag or anti-LASV IgM,
18% (125/688 had anti-LASV IgG. CFRs of patients in the
Ag+/IgM+ or Ag2/IgM+ serogroups did not differ significantly
by the presence or absence of anti-LASV IgG on the first blood
draw. In contrast, the CFR in patients with Ag+/IgM2/IgG+
was significantly lower than in Ag+/IgM2/IgG2 patients with
acute LF (p = .042, Fig. 3B, Table S4). Only six patients (two
fatal) showed an Ag+/IgM2/IgG+ serological profile. This
profile is consistent with a secondary LASV infection as
suggested previously using indirect immunofluorescent assays
[28]. Further studies of larger numbers of subjects are required
prior to concluding that secondary LASV infection can occur.
The CFR in NLFI patients with Ag2/IgM2/IgG+ was
significantly lower than in Ag2/IgM2/IgG2 patients
(p = .045).
The CFR for the subset of Ag+ subjects with an IgG test result
(+ or 2) was 71% (79/112, Fig. 3C). Ag2 patients presenting
with both anti-LASV IgM+ and IgG+ may be in the
convalescence stage of LF. The 33% (14/43) CFR of Ag2/
IgM+/IgG+ patients was significantly lower (p,.001) than the
CFR of Ag+ patients (Table S4). Most subjects presenting with
Ag2/IgM+/IgG2 or Ag2/IgM2/IgG6 serostatus are unlikely
to have presented with LF. The 37% (51/138) CFR of these
subjects (non-LF) was significantly lower (p,.001) than Ag+
subjects. Ag2/IgM+/IgG2 patients that seroconvert to anti-
LASV IgG+ (class-switching) may also be considered to be in
early LF convalescence. Out of 60 Ag2/IgM+ patients with IgG
testing, a follow-up sample and verified outcome, only nine
patients were IgG2 on the first sample, but IgG+ on the second
Figure 2. CFRs in suspected LF cases presenting to the KGH Lassa Ward by serostatus, 2008–12. Panel A: CFR by serostatus. The presence
of LASV Ag and anti-LASV IgM in serum of patients with verifiable outcomes was assessed by recombinant Ag2 and IgM2 capture ELISA,
respectively. Panel B: Alternative calculation of CFRs. Ag+/IgM6 plus Ag2/IgM+ compared to Ag2/IgM2. Statistical significance was determined
using a logistic regression model predicting CFR (Table S3). NS =not significant.
doi:10.1371/journal.pntd.0002748.g002
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indicating class-switching (data not shown). None of these
patients died.
A broad geographic distribution of LF cases in Sierra
Leone
The majority of suspected LF cases evaluated at the KGH
Lassa Laboratory from 2008–12 were residents of Kenema
District in the Eastern Province of Sierra Leone, where KGH is
located (Fig. 4). Cases with LF presenting to KGH from
outside the recognized endemic zone were recorded in
increasing frequency throughout the post-conflict period [22].
Ten of Sierra Leone’s thirteen districts had at least one
laboratory-confirmed LF case with antigenemia (Ag+/IgM6)
from 2008–2012. IgM seropositivity, which indicates exposure
to LASV, was also observed in ten of Sierra Leones thirteen
districts.
Distinct patterns of seasonal variation among suspected
LF cases with different serostatus
Studies conducted prior to the end of hostilities suggested that
the highest incidence of LF in Sierra Leone occurs during the dry
season (November to April) [1,28]. We found a similar pattern in
the post-conflict period, with a peak of antigenemic LF cases
presenting to the KGH Lassa Ward in March (Fig. 5A). Ag2/
IgM+ patients presented with a peak in the dry season (March)
and another peak in the rainy season (October; Fig. 5B). Patients
with NLFI had a distinct peak of presentation in June and July,
which begins the period of greatest rainfall (Fig. 5C).
Figure 3. Anti-LASV IgG in suspected LF patients presenting to the Kenema Government Hospital, 2011–12. Routine anti-LASV IgG
serological testing was implemented at KGH in 2011. Panel A: Percentage of patients with anti-LASV IgG by serostatus. Panel B: Case fatality rates in
patients with verifiable outcomes by LASV antigen, anti-LASV IgM, and anti-LASV IgG serostatus. Panel C: Case fatality rates in patients with verifiable
outcomes by an alternative assessment of LF status (acute =Ag+/IgM6/IgG6, convalescent =Ag2/IgM+/IgG+, nonLF=Ag2/IgM+/IgG2 or Ag2/
IgM2/IgG6 LASV antigen, anti-LASV IgM, and anti-LASV IgG serostatus. Logistic regression models predicting IgG-positivity and CFRs were used to
carry out within and between group comparisons (Table S4). NS =not significant.
doi:10.1371/journal.pntd.0002748.g003
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Age distribution of suspected LF cases
Presentation of Ag+/IgM6 patients occurred with a bimodal
frequency, with peak incidences in childhood (ages 0–9) and in
adolescence/adulthood (ages 15–39) (Fig. 6A, Table S5). In
contrast, the overall age distribution observed in Ag2/IgM+
patients showed peaked in adolescence/adulthood (ages 15–39)
(Fig. 6B). The age distribution of persons presenting with a NLFI
(Ag2/IgM2) peaked in infancy and declined with increasing age
(Fig. 6C) and was similar to the age distribution of the general
Sierra Leonean population (Fig. 6D). High CFRs were observed in
LASV antigenemic patients across all age groups (Fig. 6A). All
antigenemic infants under the age of 1 died. Deaths in antigenemic
patients (Ag+/IgM6) were bimodal, peaking in early childhood
(ages 0–9) and in adolescence/early adulthood (ages 15–29;
Fig. 6A) following the pattern of overall presentation. A similar
bimodal distribution of patient deaths was observed in Ag2/IgM+
patients (Fig. 6B). It is unclear whether there is enhanced
immunological susceptibility to severe LASV infection at certain
ages or higher exposure to the rodent reservoir. The numbers of
deaths in patients presenting with a NLFI (Ag2/IgM2) were
biased toward infants and children (Fig. 6C), but otherwise closely
resembled the age distribution of Sierra Leone’s population
(Fig. 6D). The age distributions overall and for patients who died
or were discharged for each serogroup are replotted as fitted
curves in Supplemental Fig. S1.
Female gender and self-reported pregnancy are risk
factors in LF
Significantly more females than males presented to the KGH
Lassa Ward with suspected LF in each serogroup, except for early-
stage LF (Ag+/IgM2) (Fig. 7A). Women and men in all
serogroups displayed similar CFRs (Fig. 7B). Prior studies
indicated that LF in pregnancy results in a high fetal mortality
and increased fatalities in pregnant woman, particularly in the last
trimester [22,29]. Women who self-reported as pregnant were
significantly overrepresented in the serogroups with LASV
antigenemia (Ag+/IgM2, Ag+/IgM+) compared to the Ag2
serogroups (Ag2/IgM+, Ag2/IgM2; Fig. 7C). It is unlikely that
infection with LASV would inform the subject regarding her
pregnancy status, and first trimester pregnancies are likely
Figure 4. Geographic distribution of patients presenting to the KGH with LASV antigenemia and anti-LASV IgM serpositivity, 2008–
12. Confirmed cases of LF as assessed by LASV Ag in serum or cases anti-LASV IgM are shown by year of presentation, district of residence and
frequency of cases. Panel A: Patients presenting in 2008–9. Panel B: Patients presenting in 2010. Panel C: Patients presenting in 2011. Panel D: Patients
presenting in 2012.
doi:10.1371/journal.pntd.0002748.g004
Lassa Fever in Post-Conflict Sierra Leone
PLOS Neglected Tropical Diseases | www.plosntds.org 7 March 2014 | Volume 8 | Issue 3 | e2748
underreported. We did not find a statistically significant increase in
CFR related to pregnancy, as has been noted in previous studies
[22,29]. Nevertheless, the CFR for Ag+/IgM2 pregnant women
in our study was 93%, compared with 66% of non-pregnant
women in this serogroup (Fig. 7D). The small sample size and
elevated mortality noted for all groups in our study may account
for the lack of statistical significance.
Case fatality rates in ribavirin-treated and untreated
patients
The antiviral drug ribavirin has been reported to significantly
reduce LF CFRs [18]. We observed that the CFR in Ag+/IgM2
patients treated with ribavirin was 44% compared to 92% in
untreated subjects (Fig. 8). Fewer ribavirin-treated Ag+/IgM+
patients died than untreated patients, but the number of patients
in this group was small and this difference was not statistically
significant. Most Ag+ subjects whether treated or not showed a
decline in LASV antigenemia; among 69 antigenemic subjects
with a second blood draw (generally 1–2 days later), only 10
showed any increase in antigen load, with 16/69 with a similar
load on the second blood draw and most (43/69) with a decreased
load. Of these 43 patients, 29 had greater than a 10-fold reduction
in virus antigen on the second blood draw. There was no
difference in survival between ribavirin-treated and untreated
Ag2/IgM+ patients. Unexpectedly, mortality in persons with
NLFI (Ag2/IgM2) was lower in ribavirin-treated versus untreat-
ed patients.
Discussion
The civil war that ravaged Sierra Leone from 1991 to 2002
displaced hundreds of thousands of people, destroyed health and
education facilities and disrupted the training of a generation of
healthcare workers. Many skilled health and research professionals
fled the country. A decade later, Sierra Leone is still struggling to
rebuild its health sector, but improvement in many areas is being
realized. The results reported here highlight significant progress
toward one of Sierra Leone’s major public health goals – effective
management of the LF threat. A leading LF clinical and research
center has been reestablished at KGH. Numbers of suspected LF
cases presenting at KGH have increased dramatically with the end
of hostilities, which can be attributed, in part, to the efforts of the
KGH LF outreach team, who have sensitized healthcare providers
in rural health centers to the LF threat and alerted them to the
renewed availability of LF testing and treatment at KGH. The
increased ability to safely move about the country has likely also
increased the ability of persons with LF to present for care, but
may have lead to transmission to new areas.
The observed CFR in LASV antigenemic patients presenting to
KGH during the period from 2008–12 was 69%. Studies
published in the pre-conflict period reported overall CFRs in
similar populations of LF patients of 8 to 38% [1,6,14,16].
Differences in sensitivity of the different assays used to detect
LASV infection coupled with alternative paradigms for classifying
LF patients may account for the differences in CFRs. RT-PCR
and virus culture are capable of detecting lower levels of LASV
than immunoassays [14,15,27]. Furthermore, subjects presenting
without viremia, but with anti-LASV IgM, were included in the
diagnosis of acute LF in previous studies. [27,28]. It is important to
note that these prior studies used different assays than those
employed in the current studies. For KGH patients presenting
with anti-LASV IgM from 2008–12 the CFR was 29%. The
combined CFR of Ag+ plus IgM+ patients presenting to KGH was
49%, which is still higher than observed in most studies prior to
the civil conflict. In contrast to other viral infections in which
antiviral IgM antibodies are replaced with predominantly IgG
antibodies, anti-LASV IgM antibodies, particularly to the LASV
glycoprotein and Z protein, often persist for months to years after
Figure 5. Monthly distribution of suspected LF cases present-
ing to the KGH Lassa Ward by serostatus, 2008–2012. Panel A:
antigenemic Lassa fever cases (Ag+/IgM6). Panel B: Patients with serum
anti-LASV IgM (Ag2/IgM+). Panel C: Patients with no Lassa virus
seropositivity (Ag2/IgM2). The monthly frequency distributions
differed between each of the serostatus group comparisons as assessed
using a Poisson regression model (p,.001 for all serostatus compar-
isons; data not shown).
doi:10.1371/journal.pntd.0002748.g005
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LASV exposure [23]. Studies in non human primate also indicated
that anti-LASV IgM antibodies persist [30], leading us to speculate
that LASV infection dysregulates antibody class-switching [23].
These studies suggest that not all febrile patients presenting with
anti-LASV IgM in the absence of antigenemia have recent LASV
infection, and that including all IgM+ patients as acute LF
underestimates the CFR of this disease.
It is worth mentioning that CFRs in patients presenting to
health care facilities represent only the most severe LASV
infections. Our hospital-based studies were not designed to
determine overall exposure rates to LASV. Moreover, individuals
that develop less severe manifestations of the infection or that
remain asymptomatic may not seek medical care. As discussed by
others previously [28,31,32], hospital-based CFRs do not reflect
overall mortality rates caused by LASV infection, which are likely
to be considerably lower.
To guide clinical management of patients with LF, it is
important to monitor follow-up samples for changes in levels of
anti-LASV antibodies. A rise in IgM titers or IgM to IgG
seroconversion in a nonantigenemic patient indicates a post-acute
stage of LF. Results of our recent clinical trial of the LF diagnostic
assay system revealed that patients with changing IgM or IgG
levels represent a minority of IgM+ patients presenting with febrile
illnesses to the KGH Lassa Ward overall (Table S2, unpublished
Figure 6. Age distribution of cases presenting to the KGH Lassa Ward, 2008–12. Panel A: Age distributions of patients presenting while
antigenemic (Ag+/IgM6). Panel B: Age distributions of nonantigenemic patients presenting with serum anti-LASV IgM (Ag2/IgM+). Panel C: Age
distributions of nonantigenemic patients presenting without anti-LASV IgM seropositivity (Ag2/IgM2). In Panels A–C yellow portion of bars
represent patients who were discharged and black portion of bars represent patients who died. Panel D: Age demographic for the population of
Sierra Leone (2010 estimate). Among patients who died, the age distributions differed significantly between the Ag+/IgM6 and Ag2/IgM2 groups
(p = .005). Distributional comparisons were carried out using the Kolmogorov-Smirnov technique (Table S5).
doi:10.1371/journal.pntd.0002748.g006
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data). Suspected cases presenting with sustained anti-LASV IgM
levels in the absence of LASV antigenemia likely have febrile
illnesses other than LF. We found that LF screening with the
ReLASV diagnostic assays was capable of identifying great than
95% of active LF cases (acute and post-acute) as confirmed by RT-
PCR (Table S2).
While the majority of LF cases presenting to KGH were from
the long-recognized endemic Kenema and Bo Districts, cases were
also confirmed in areas of Sierra Leone that had not previously
been considered to have a high risk for LF. We observed LF cases
from ten of Sierra Leone’s thirteen districts, with numerous cases
from outside the traditional endemic zone. These results suggest
that LASV may be more broadly distributed across Sierra Leone
than was observed prior to the civil conflict. Alternatively,
increased awareness due to outreach efforts and greater access
for testing/transport of suspected patients to Kenema may account
for the increased numbers of cases reporting from these new
regions. It is also possible that LASV-infected Mastomys natalensis
populations are expanding to new areas. We also cannot exclude
the possibility that Ag+ or IgM+ persons from other regions were
exposed to LASV while previously living in or transiting through
the classically recognized endemic areas or from contact with
infected visitors, especially considering the massive human
migrations that have occurred in post-war Sierra Leone.
The highest incidence of LF in Sierra Leone occurs during the
dry season (November to April), a pattern also observed prior to
the conflict [31]. Our studies also confirmed reports conducted
prior to the civil conflict by indicating that infants, children, young
adults, and pregnant women are disproportionately impacted by
LF [29,33,34]. Deaths in patients presenting while LASV
antigenemic were highest in infants and children under 9 years
of age and adolescents and adults less than 29 years of age.
Figure 7. Gender and self-reported pregnancy status of suspected Lassa fever cases presenting to the KGH Lassa Ward, 2008–2012.
Panel A: Frequency of suspected Lassa fever cases by gender and serostatus. Panel B: Cases fatality rates by gender and serostatus. Panel C:
Percentage of female patients of childbearing age with self-reported pregnancy status by serostatus. Panel D: Case fatality rates in female patients
with self-reported pregnancy status Pregnancies are self-reported and therefore likely underestimated as pregnancy tests were not routinely
available. Logistic regression was used for group comparisons (Tables S6 and S7). NS =not significant.
doi:10.1371/journal.pntd.0002748.g007
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Women who self-reported as pregnant were significantly overrep-
resented in serogroups with LASV antigenemia. From 2008 to
2012 the percentage of children under five and pregnant women
presenting to the KGH Lassa Ward increased from approximately
7% to over 18% of children and from 0% to 20% of women, with
significant increases in 2010 (Table S7). These increases are in part
attributable to Sierra Leone’s groundbreaking free healthcare
program for pregnant and lactating women and children under
five years of age [35]. Despite these advances, Sierra Leone is still
faced with high maternal, infant, and child mortality rates which
may in part be attributable to LF, especially considering that
LASV infection in persons with naı¨ve or altered immune status,
such as in childhood and pregnancy, appears to lead to more
severe disease.
The CFR in Ag+/IgM2 patients treated with ribavirin was
lower than in untreated subjects (44% vs. 92%). However, these
studies were not designed as a clinical trial and therefore do not
permit conclusions as to the efficacy of ribavirin treatment in LF.
Furthermore, the number of fatalities in treated patients was still
unacceptably high, a finding largely attributable to delayed
initiation of treatment [18]. From 2008–12, fewer than 25%
patients with LF presented within 7 days post-symptom onset. Our
lateral flow immunoassay for LASV antigen may play a role in
rectifying this situation since it can be disseminated to outlying
clinics and laboratories and reliably and safely performed by
persons with limited laboratory training. The high CFR in
ribavirin-treated subjects observed in the current studies under-
scores the need to develop more effective or supplemental
treatments for LF. Controlled clinical studies of ribavirin efficacy
are also needed, which can serve as a prelude to clinical trials of
other LF treatments, including immunotherapeutics, currently in
the development pipeline. Lastly, we speculate that the unexpected
decrease in CFR in NLFI patients treated with ribavirin may
indicate a response of unrecognized non-LASV viral infections to
this drug, which has broad-spectrum antiviral properties [36]. The
enhanced laboratory diagnostic capacity may serve to elucidate
the pathogens inducing NLFI in patients presenting to the KGH
Lassa Ward.
Supporting Information
Figure S1 Kernel-smoothed age distributions of sus-
pected LF cases presenting to the KGH Lassa Ward, by
serostatus group, 2008–12: An alternative presentation
of Fig. 6. Panel A: Smoothed age distributions for patients
presenting while antigenemic (Ag+/IgM6, green line), patients
presenting with serum anti-LASV IgM (Ag2/IgM+, red line), or
no LASV seropositivity (Ag2/IgM2, blue line). Panel B:
Smoothed age distributions for patients that died by serostatus.
Panel C: Smoothed age distributions among patients who were
discharged from the KGH by serostatus. Dotted line in panels A–
C is age demographic for the population of Sierra Leone (2010
estimate). Among patients who died, the age distributions differed
significantly between the Ag+/IgM+2 and Ag2/IgM2 groups
(p = .005). A Gaussian kernel smoothing technique was used to
generate the smoothed distribution curves. The distributional
comparisons were carried out using the Kolmogorov-Smirnov
technique (Table S5).
(TIF)
Table S1 (corresponds to Fig. 1): Characteristics of
study subjects. This table provides characteristics of study
subjects by outcome, admission status, district, age, gender
pregnancy status and duration of illness.
(DOC)
Table S2 Performance of the Recombinant Lassa
Diagnostics versus RT-PCR in a clinical study conducted
at KGH in 2012–13. This table provides a summary of the
performance of the immunoassays used in to evaluate the
serostatus of suspected LF patients presenting to KGH.
(DOC)
Table S3 (corresponds to Fig. 2): Logistic regression
results showing serostatus case fatality ratios. This table
provides confidence intervals and p values for the data presented
in Figure 2.
(DOC)
Table S4 (corresponds to Fig. 3): Logistic regression
results showing IgG-positivity ratios and serostatus case
fatality ratios by IgG status. This table provides confidence
intervals and p values for the data presented in Figure 3.
(DOC)
Table S5 (corresponds to Fig. 6 and Supplemental Fig.
S1): Comparison of age distributions among serostatus
groups by survival outcome. This table provides p values for
the data presented in Figure 6 and Supplemental Fig. S1.
(DOC)
Table S6 (corresponds to Figs. 7a and 7b): Logistic
regression results showing gender ratios and serostatus
case fatality ratios by gender. This table provides confidence
intervals and p values for the data presented in Figure 7a and 7b.
(DOC)
Table S7 (corresponds to Figs. 7c and 7d): Logistic
regression results showing pregnancy ratios and sero-
status case fatality ratios by self-reported pregnancy
status. This table provides confidence intervals and p values for
the data presented in Figure 7c and 7d.
(DOC)
Figure 8. Case fatality rates for suspected LF cases by ribavirin
treatment status and serostatus. The presence of LASV Ag in serum
of patients with observed survival outcomes and verified treatment
status was assessed by recombinant Ag2 and IgM-capture ELISA.
Statistical significance for within and between group comparisons was
determined using a multivariate logistic regression model (Table S9).
NS = not significant.
doi:10.1371/journal.pntd.0002748.g008
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Table S8 Selected characteristics by year of presenta-
tion. This table provides p values for differences in numbers of
patients by gender, pregnancy status and age by year of
presentation.
(DOC)
Table S9 (corresponds to Figure 8): Logistic regression
results showing serostatus case fatality ratios by
treatment status. This table provides confidence intervals and
p values for the data presented in Figure 8.
(DOC)
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